TITLE

Duloxetine in the treatment of major depressive disorder: an open-label study

AUTHOR(S)
Hudson, James I.; Perahia, David G.; Gilaberte, Inmaculada; Fujun Wang; Watkin, John G.; Detke, Michael J.
PUB. DATE
January 2007
SOURCE
BMC Psychiatry;2007, Vol. 7, p43
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Major depressive disorder (MDD) is a chronic and highly disabling condition. Existing pharmacotherapies produce full remission in only 30% to 40% of treated patients. Antidepressants exhibiting dual reuptake inhibition of both serotonin (5-HT) and norepinephrine (NE) may achieve higher rates of remission compared with those acting upon a single neurotransmitter. In this study, the safety and efficacy of duloxetine, a potent dual reuptake inhibitor of 5-HT and NE, were examined. Methods: Patients (N = 533) meeting DSM-IV criteria for MDD received open-label duloxetine (60 mg once a day [QD]) for 12 weeks during the initial phase of a relapse prevention trial. Patients were required to have a 17-item Hamilton Rating Scale for Depression (HAMD17) total score ≥18 and a Clinical Global Impression of Severity (CGI-S) score ≥4 at baseline. Efficacy measures included the HAMD17 total score, HAMD17 subscales, the CGI-S, the Patient Global Impression of Improvement (PGI-I) scale, Visual Analog Scales (VAS) for pain, and the Symptom Questionnaire, Somatic Subscale (SQ-SS). Quality of life was assessed using the Sheehan Disability Scale (SDS) and the Quality of Life in Depression Scale (QLDS). Safety was evaluated by recording spontaneously-reported treatment-emergent adverse events, changes in vital signs and laboratory analytes, and the Patient Global Impression of Sexual Function (PGI-SF) scale. Results: The rate of discontinuation due to adverse events was 11.3%. Treatment-emergent adverse events reported by ≥10% duloxetine-treated patients were nausea, headache, dry mouth, somnolence, insomnia, and dizziness. Following 12 weeks of open-label duloxetine therapy, significant improvements were observed in all assessed efficacy and quality of life measures. In assessments of depression severity (HAMD17, CGI-S) the magnitude of symptom improvement continued to increase at each study visit, while for painful physical symptoms the onset of improvement was rapid and reached a maximum after 2 to 3 weeks of treatment. Conclusion: In this open-label phase of a relapse prevention study, duloxetine (60 mg QD) was shown to be safe and effective in the treatment of MDD.
ACCESSION #
29962959

 

Related Articles

  • Relative Antidepressant Efficacy of Venlafaxine and SSRIs: Sex-Age Interactions. Thase, Michael E.; Entsuah, Richard; Cantillon, Marc; Kornstein, Susan G. // Journal of Women's Health (15409996);Sep2005, Vol. 14 Issue 7, p609 

    Objective: To investigate whether differences in antidepressant efficacy are moderated by an interaction of age and gender. Methods: A pooled dataset from eight randomized, controlled trials of patients with major depressive disorder (MDD) was reanalyzed to compare remission rates following...

  • Pharmacokinetics of Reboxetine in Volunteers with Hepatic Impairment. Tran, A.; Laneury, J.; Duchêne, P.; Jannuzzo, M.G.; Fleishaker, J.C.; Houin, G.; Rampal, P. // Clinical Drug Investigation;2000, Vol. 19, p473 

    Objective: Reboxetine is a unique selective norepinephrine (noradrenaline) reuptake inhibitor (selective NRI) that is effective and well tolerated at a dosage of 8 to 10 mg/day in the short- and long-term treatment of depression. The objective of the study was to assess reboxetine...

  • A Comparison of Nortriptyline and Amitriptyline in Depression. Rose, John T.; Leahy, M. R.; Martin, Ian C. A.; Westhead, T. T. // British Journal of Psychiatry;Nov65, Vol. 111 Issue 480, p1101 

    The article discusses the study that compares nortriptyline and amitriptyline in depression. It involves 37 in-patients and 13 out-patients of a psychiatric unit, suffering from primary depressive disorders and classified into reactive and endogenous depressions. Amitriptyline is given in doses...

  • SSRIs widely used for children. Lucas, Beverly D. // Patient Care;8/15/1999, Vol. 33 Issue 13, p18 

    reveals that family physicians and pediatricians prescribe selective serotonin reuptake inhibitors (SSRI) for children and adolescents. Survey conducted by the University of North Carolina at Chapel Hill; Most common reason for prescribing an SSRI; Percentage of respondents who prescribed an...

  • Relighting the Inner Flame. Klotter, Jule // Townsend Letter;Jan2007, Issue 282, p72 

    The article discusses the significance of selective serotonin reuptake inhibitors (SSRI) in treating mental depression in the U.S. The author discusses the withdrawal effects of the drug and argues that the drugs are necessary for the patient's health. Moreover, she emphasizes the importance of...

  • Sustained administration of the antidepressant venlafaxine in rats: pharmacokinetic and pharmacodynamic findings. Wikell, Cecilia; Hjorth, Stephan; Apelqvist, Gustav; Kullingsjö, Johan; Lundmark, Jons; Bergqvist, Peter B. F.; Bengtsson, Finn // Naunyn-Schmiedeberg's Archives of Pharmacology;Apr2001, Vol. 363 Issue 4, p448 

    Rats were administered venlafaxine (10 mg/kg per day) for 14 days by using subcutaneously implanted osmotic minipumps. The present study assessed the distribution of VEN in different compartments, whether the VEN concentration in the compartments correlated, the effect of VEN on dialysate...

  • A REVIEW: HYPOTHESIS OF DEPRESSION AND ROLE OF ANTIDEPRESSANT DRUGS. Kharade, S. M.; Gumate, D. S.; Naikwade, N. S. // International Journal of Pharmacy & Pharmaceutical Sciences;2010 Supplement 4, Vol. 2, p3 

    There is very vast empirical work that directly assesses the neurobiological association of neurochemicals and biochemical super factors with the liability to depression. Therefore, as a means of providing a framework for future research, this article outline the path physiology arises as a...

  • The comparison between therapeutic effects of different classes of antidepressant drugs in treatment of genetical and reactional depression. Molavi, Parviz; Mansoureh, Karimollahi; Faridi, M.; Mohammadnia, H.; Dailami, P.; Arab, R.; Derakshani, F. // Annals of General Psychiatry;2008 Supplement 1, Vol. 7, Special section p1 

    Background Depression as a common psychiatric disorder can occur in two types: endogenous or genetic and exogenous or reactional. These two types of depression, from the point of view of response speed to treatment and type of appropriate drug for treatment are different. This study has been...

  • Strategies for Managing Depression Refractory to Selective Serotonin Reuptake Inhibitor Treatment: A Survey of Clinicians. Mischoulon, David; Nierenberg, Andrew A; Kizilbash, Leena; Rosenbaum, Jerrold F; Fava, Maurizio // Canadian Journal of Psychiatry;Jun2000, Vol. 45 Issue 5, p476 

    Objective: To examine treatment practices in cases where selective serotonin reuptake inhibitors (SSRIs) are ineffective.Methods: We surveyed 801 clinicians (including 630 psychiatrists) attending the Massachusetts General Hospital's annual psycho-pharmacology review course. Clinicians were...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics